Loading...
•
Jun 30, 2022
Ironwood Pharmaceuticals Q2 2022 Earnings Report
Reported second quarter 2022 results and maintained full year guidance.
Key Takeaways
Ironwood Pharmaceuticals reported positive momentum in Q2 2022, with LINZESS prescription demand growth and progress in clinical trials. The company ended the quarter with $504 million in cash and cash equivalents and reiterated its 2022 full-year guidance.
LINZESS EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year.
GAAP net income was $37 million and adjusted EBITDA was $56 million.
The company completed its Board of Directors authorized share repurchase program and repaid the remaining principal amount of the 2022 Convertible Notes in cash.
2022 guidance of U.S. LINZESS net sales growth of low single digits %, total Ironwood revenue of $420 to $430 million and adjusted EBITDA of >$250 million was reiterated.
Forward Guidance
Ironwood Pharmaceuticals reiterates its 2022 guidance.
Positive Outlook
- U.S. LINZESS net sales growth of low single digits %
- Total Ironwood revenue of $420 to $430 million
- Adjusted EBITDA of >$250 million
- Continued focused investments
- Commitment to reaching new patients to drive prescription demand growth moving forward
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...